Galactosemia type III, or UDP-galactose 4'-epimerase deficiency, is a rare hereditary disorder of galactose metabolism caused by pathogenic variants in the GALE gene. It is inherited primarily in an autosomal recessive pattern and alters the Leloir pathway, leading, in its generalized forms, to accumulation of galactose-1-phosphate and imbalances in sugar nucleotides essential for cellular function.
Galactosemia type 3 (GALE gene)
The GALE gene provides the instructions for producing the enzyme UDP-galactose 4'-epimerase, a key protein in the Leloir pathway. This enzyme catalyzes the reversible conversion between UDP-galactose and UDP-glucose and also participates in the balance of other sugar nucleotides necessary for synthesizing glycoproteins and glycolipids. Therefore, its function is important both for processing galactose from the diet and for maintaining normal cellular processes related to glycosylation.
When pathogenic variants exist in GALE, enzyme activity can be variably reduced. The disease constitutes a clinical spectrum that includes a peripheral form, generally benign and limited to blood cells; an intermediate form; and a generalized form, in which the deficiency affects multiple tissues and can resemble classic galactosemia. In severe forms, exposure to lactose or galactose favors the accumulation of galactose-1-phosphate and galactitol, in addition to reducing the availability of UDP-galactose, with hepatic, ocular, and neurological involvement. Inheritance is autosomal recessive, so two pathogenic variants in GALE are required. It is a very rare disease; forms detected by neonatal screening are more common than the generalized form and have been described more frequently in some population groups, although prevalence data are limited.
Symptoms
The age of onset and severity depend on the degree and tissue distribution of the enzyme deficiency. The peripheral form is usually asymptomatic and is identified by neonatal screening or biochemical studies. The generalized form manifests in the neonatal period, after intake of breast milk or formula with lactose, with symptoms similar to galactosemia type I: feeding refusal, vomiting, weight loss, jaundice, hepatomegaly, impaired liver function, aminoaciduria, and cataracts. In some patients, long-term complications may persist, such as developmental delay, short stature, sensorineural hearing loss, or skeletal abnormalities.
Disease management
Management depends on the clinical and biochemical subtype. In newborns with suspected GALE deficiency, it is recommended to start early galactose/lactose restriction while diagnostic characterization is completed. In the peripheral form, once confirmed, strict restrictions may not be necessary to maintain. In the generalized form, the main treatment is a diet restricted in galactose and lactose to prevent or correct acute manifestations, although excessive restriction should be avoided because UDP-galactose is necessary for the endogenous synthesis of glycoconjugates. Monitoring includes monitoring of galactose-1-phosphate or galactitol, growth, development, vision, hearing, and liver function. There is currently no approved enzyme replacement therapy.
Genes analyzed
Bibliography
Fridovich-Keil J, Bean L, He M, et al. Epimerase Deficiency Galactosemia. 2011 Jan 25 [updated 2021 Mar 4]. In: Adam MP, Bick S, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025.
Tong F, Yang R, Hong F, et al. A first case report of UDP-galactose-4'-epimerase deficiency in China: genotype and phenotype. J Pediatr Endocrinol Metab. 2016 Mar;29(3):379-83.
